Somatostatin Receptor Expression Is Associated With Metastasis and Patient Outcome in Pulmonary Carcinoid Tumors.

摘要: CONTEXT Pulmonary carcinoids (PCs) belong to neuroendocrine tumors that often overexpress somatostatin receptors (SSTRs). This overexpression provides a molecular basis for tumor imaging and treatment with analogs. OBJECTIVE To evaluate SSTR1 SSTR5 distribution in large set of PC investigate whether the expression is associated clinicopathological outcome data. DESIGN, SETTING, AND PATIENTS retrospective study was conducted at Helsinki University Hospital Helsinki. It included 178 coupled patients' clinical data retrieved through Finnish biobanks. After histological reclassification, tissue specimens were processed into next-generation microarray format stained immunohistochemically monoclonal antibodies. MAIN OUTCOME MEASURE tumors. RESULTS Expression detected 52%, 75%, 56%, 16%, 32% tumors, respectively. Membrane-bound staining observed all receptors. SSTR2 negativity SSTR4 positivity lymph node involvement time surgery (P = 0.014 P 0.017, respectively) distant metastasis 0.027 0.015, respectively). SSTR3 increased risk shorter survival [P 0.046, hazard ratio (HR) 4.703, 95% CI 1.027 21.533; 0.013, HR 6.64, 1.48 29.64, respectively], whereas improved 0.021, 0.167, 0.037 0.765; 0.022, 0.08, 0.01 0.70, CONCLUSION PCs. As SSTR tumor's metastatic potential patient outcome, these may offer possibility individualized prognosis estimation.